oncolytic adenovirus therapy (Tessa therapeutics/AstraZeneca/Baylor College of Medicine)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug Nameoncolytic adenovirus therapy (Tessa therapeutics/AstraZeneca/Baylor College of Medicine)
Drug Alias NameCAdTetraCD44v6.bispecific T-cell engager + CAdTrio (Tessa therapeutics/AstraZeneca/Baylor College of Medicine)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Oncolytic virus +[4] 
Mechanisms of ActionCD44 antigen modulatorsImmunostimulantsT lymphocytes stimulants
TargetsCD44 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesTessa Therapeutics Pte LtdAstrazeneca PlcBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A